Long-chain omega-3 fatty acids and the brain: a review of the independent and shared effects of EPA, DPA and DHA

Omega-3 polyunsaturated fatty acids (PUFAs) exhibit neuroprotective properties and represent a potential treatment for a variety of neurodegenerative and neurological disorders. However, traditionally there has been a lack of discrimination between the different omega-3 PUFAs and effects have been broadly accredited to the series as a whole. Evidence for unique effects of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) and more recently docosapentaenoic acid (DPA) is growing. For example, beneficial effects in mood disorders have more consistently been reported in clinical trials using EPA; whereas, with neurodegenerative conditions such as Alzheimer’s disease, the focus has been on DHA. DHA is quantitatively the most important omega-3 PUFA in the brain, and consequently the most studied, whereas the availability of high purity DPA preparations has been extremely limited until recently, limiting research into its effects. However, there is now a growing body of evidence indicating both independent and shared effects of EPA, DPA and DHA. The purpose of this review is to highlight how a detailed understanding of these effects is essential to improving understanding of their therapeutic potential. The review begins with an overview of omega-3 PUFA biochemistry and metabolism, with particular focus on the central nervous system (CNS), where DHA has unique and indispensable roles in neuronal membranes with levels preserved by multiple mechanisms. This is followed by a review of the different enzyme-derived anti-inflammatory mediators produced from EPA, DPA and DHA. Lastly, the relative protective effects of EPA, DPA and DHA in normal brain aging and the most common neurodegenerative disorders are discussed. With a greater understanding of the individual roles of EPA, DPA and DHA in brain health and repair it is hoped that appropriate dietary recommendations can be established and therapeutic interventions can be more targeted and refined.

[1]  T. Bliss,et al.  A synaptic model of memory: long-term potentiation in the hippocampus , 1993, Nature.

[2]  G. Michael,et al.  Omega‐3 fatty acids reverse age‐related decreases in nuclear receptors and increase neurogenesis in old rats , 2010, Journal of neuroscience research.

[3]  M. Lynch,et al.  Age-related changes in synaptic function: analysis of the effect of dietary supplementation with ω-3 fatty acids , 1999, Neuroscience.

[4]  J. Schneider,et al.  Plasma and brain fatty acid profiles in mild cognitive impairment and Alzheimer's disease. , 2012, Journal of Alzheimer's disease : JAD.

[5]  Chunghee Lee,et al.  Molecular Species of Diacylglycerols and Phosphoglycerides and the Postmortem Changes in the Molecular Species of Diacylglycerols in Rat Brains , 1991, Journal of neurochemistry.

[6]  F. LaFerla,et al.  Diffusion of docosahexaenoic and eicosapentaenoic acids through the blood–brain barrier: An in situ cerebral perfusion study , 2009, Neurochemistry International.

[7]  M. Garg,et al.  Docosapentaenoic acid (22:5n-3): a review of its biological effects. , 2011, Progress in lipid research.

[8]  O. Shido,et al.  Omega-3 Polyunsaturated Fatty Acids Enhance Neuronal Differentiation in Cultured Rat Neural Stem Cells , 2013, Stem cells international.

[9]  S. Feller,et al.  Polyunsaturated docosahexaenoic vs docosapentaenoic acid-differences in lipid matrix properties from the loss of one double bond. , 2003, Journal of the American Chemical Society.

[10]  C. Serhan,et al.  Total synthesis of the anti-inflammatory and pro-resolving lipid mediator MaR1n-3 DPA utilizing an sp(3) -sp(3) Negishi cross-coupling reaction. , 2014, Chemistry.

[11]  H. Arrighi,et al.  Prevalence of Apolipoprotein E4 Genotype and Homozygotes (APOE e4/4) among Patients Diagnosed with Alzheimer’s Disease: A Systematic Review and Meta-Analysis , 2011, Neuroepidemiology.

[12]  D. Moras,et al.  Molecular recognition of agonist ligands by RXRs. , 2002, Molecular endocrinology.

[13]  C. Serhan,et al.  Resolution phase lipid mediators of inflammation: agonists of resolution. , 2013, Current opinion in pharmacology.

[14]  J. Li.  Negishi Cross-Coupling Reaction , 2021, Name Reactions.

[15]  H. Garda,et al.  Possible compensation of structural and viscotropic properties in hepatic microsomes and erythrocyte membranes of rats with essential fatty acid deficiency. , 1994, Journal of lipid research.

[16]  Dana Kilroy,et al.  Eicosapentaenoic acid confers neuroprotection in the amyloid-β challenged aged hippocampus , 2007, Neurobiology of Aging.

[17]  T. Perlmann,et al.  Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. , 2000, Science.

[18]  K. Nozaki,et al.  Proliferation of neuronal precursor cells in the dentate gyrus is accelerated after transient forebrain ischemia in mice , 1999, Brain Research.

[19]  M. Lynch,et al.  Modulation of amyloid‐β‐induced and age‐associated changes in rat hippocampus by eicosapentaenoic acid , 2007, Journal of neurochemistry.

[20]  C. Serhan,et al.  Protectins and maresins: New pro-resolving families of mediators in acute inflammation and resolution bioactive metabolome. , 2015, Biochimica et biophysica acta.

[21]  M. Lynch,et al.  The polyunsaturated fatty acids, EPA and DPA exert a protective effect in the hippocampus of the aged rat , 2011, Neurobiology of Aging.

[22]  Noor Aini Mohd Yusoff,et al.  Docosahexaenoic acid-concentrated fish oil supplementation in subjects with mild cognitive impairment (MCI): a 12-month randomised, double-blind, placebo-controlled trial , 2012, Psychopharmacology.

[23]  S. Shaikh,et al.  Docosahexaenoic acid affects cell signaling by altering lipid rafts. , 2005, Reproduction, nutrition, development.

[24]  J. Juillard,et al.  [Parkinson disease]. , 1985, Revue de l'infirmiere.

[25]  D. Mischoulon,et al.  Are omega-3 fatty acids antidepressants or just mood-improving agents? The effect depends upon diagnosis, supplement preparation, and severity of depression , 2012, Molecular Psychiatry.

[26]  F. Cicchetti,et al.  Beneficial effects of dietary omega‐3 polyunsaturated fatty acid on toxin‐induced neuronal degeneration in an animal model of Parkinson's disease , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  Hee-Yong Kim,et al.  Effect of Docosahexaenoic Acid on the Synthesis of Phosphatidylserine in Rat Brain Microsomes and C6 Glioma Cells , 1998, Journal of neurochemistry.

[28]  Carl W. Cotman,et al.  Deficient Liver Biosynthesis of Docosahexaenoic Acid Correlates with Cognitive Impairment in Alzheimer's Disease , 2010, PloS one.

[29]  E. Morya,et al.  Omega-3 deficiency and neurodegeneration in the substantia nigra: involvement of increased nitric oxide production and reduced BDNF expression. , 2014, Biochimica et biophysica acta.

[30]  Sang Beom Jun,et al.  Docosahexaenoic acid promotes hippocampal neuronal development and synaptic function , 2009, Journal of neurochemistry.

[31]  B. Anderton,et al.  The Ageing Brain , 2003 .

[32]  G. Barceló-Coblijn,et al.  Alpha-linolenic acid and its conversion to longer chain n-3 fatty acids: benefits for human health and a role in maintaining tissue n-3 fatty acid levels. , 2009, Progress in lipid research.

[33]  C. Serhan,et al.  Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions , 2009, The Journal of experimental medicine.

[34]  Zhi-li Liu,et al.  Effects of docosahexaenoic acid on the survival and neurite outgrowth of rat cortical neurons in primary cultures. , 2005, The Journal of nutritional biochemistry.

[35]  R. Curi,et al.  Comparative effects of DHA and EPA on cell function. , 2009, Pharmacology & therapeutics.

[36]  O. Shido,et al.  Docosahexaenoic acid promotes neuronal differentiation by regulating basic helix–loop–helix transcription factors and cell cycle in neural stem cells , 2009, Neuroscience.

[37]  J. Brenna,et al.  The influence of dietary docosahexaenoic acid and arachidonic acid on central nervous system polyunsaturated fatty acid composition. , 2007, Prostaglandins, leukotrienes, and essential fatty acids.

[38]  D. Butterfield,et al.  Redox proteomics and the dynamic molecular landscape of the aging brain , 2014, Ageing Research Reviews.

[39]  H. Milon,et al.  Effect of low intake of n−3 fatty acids during development on brain phospholipid fatty acid composition and exploratory behavior in rats , 1991, Lipids.

[40]  M. Masoodi,et al.  The low levels of eicosapentaenoic acid in rat brain phospholipids are maintained via multiple redundant mechanisms , 2013, Journal of Lipid Research.

[41]  L. Marnett,et al.  Spatial Requirements for 15-(R)-Hydroxy-5Z,8Z,11Z,13E-eicosatetraenoic Acid Synthesis within the Cyclooxygenase Active Site of Murine COX-2 , 2000, The Journal of Biological Chemistry.

[42]  D. Mozaffarian,et al.  (n-3) fatty acids and cardiovascular health: are effects of EPA and DHA shared or complementary? , 2012, The Journal of nutrition.

[43]  O. Lindvall,et al.  Stroke-Induced Neurogenesis in Aged Brain , 2005, Stroke.

[44]  Lars-Olof Wahlund,et al.  Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. , 2006, Archives of neurology.

[45]  Leslie K. Ferrarelli,et al.  The role of DNA repair in brain related disease pathology. , 2013, DNA repair.

[46]  G. Kempermann,et al.  Neurogenesis in the adult hippocampus , 2007, Cell and Tissue Research.

[47]  T. Willson,et al.  Polyunsaturated fatty acids including docosahexaenoic and arachidonic acid bind to the retinoid X receptor alpha ligand-binding domain. , 2004, Molecular & cellular proteomics : MCP.

[48]  M. Vohl,et al.  Plasma n-3 fatty acid response to an n-3 fatty acid supplement is modulated by apoE ɛ4 but not by the common PPAR-α L162V polymorphism in men , 2009, British Journal of Nutrition.

[49]  J. Deslypere,et al.  Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes, and adipose tissue: an 18-month controlled study. , 1997, Journal of lipid research.

[50]  M. Muldoon,et al.  Generation and Dietary Modulation of Anti-Inflammatory Electrophilic Omega-3 Fatty Acid Derivatives , 2014, PloS one.

[51]  P. Barberger‐Gateau,et al.  Low plasma eicosapentaenoic acid and depressive symptomatology are independent predictors of dementia risk. , 2008, The American journal of clinical nutrition.

[52]  D. Holtzman,et al.  Deciphering Alzheimer disease. , 2012, Cold Spring Harbor perspectives in medicine.

[53]  O. Shido,et al.  Docosahexaenoic acid promotes neurogenesis in vitro and in vivo , 2006, Neuroscience.

[54]  M. Lynch,et al.  Age-related changes in synaptic function: analysis of the effect of dietary supplementation with omega-3 fatty acids. , 1999, Neuroscience.

[55]  Bill X. Huang,et al.  Phosphatidylserine in the brain: metabolism and function. , 2014, Progress in lipid research.

[56]  J. Buckley,et al.  Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial , 2011, British Journal of Nutrition.

[57]  M. Lynch,et al.  Increased IL-1β in cortex of aged rats is accompanied by downregulation of ERK and PI-3 kinase , 2004, Neurobiology of Aging.

[58]  C. Serhan,et al.  Specialized pro-resolving lipid mediators in the inflammatory response: An update. , 2010, Biochimica et biophysica acta.

[59]  M. Lynch,et al.  Docosahexaenoic acid-induced changes in phospholipids in cortex of young and aged rats: a lipidomic analysis. , 2007, Prostaglandins, leukotrienes, and essential fatty acids.

[60]  Shankuan Zhu,et al.  Effect of n-3 PUFA supplementation on cognitive function throughout the life span from infancy to old age: a systematic review and meta-analysis of randomized controlled trials. , 2014, The American journal of clinical nutrition.

[61]  D. Horrobin,et al.  Ethyl-EPA in Alzheimer's disease--a pilot study. , 2004, Prostaglandins, leukotrienes, and essential fatty acids.

[62]  R. Gibson,et al.  Elongase Reactions as Control Points in Long-Chain Polyunsaturated Fatty Acid Synthesis , 2011, PloS one.

[63]  L. Bubacco,et al.  Structural and Morphological Characterization of Aggregated Species of α-Synuclein Induced by Docosahexaenoic Acid , 2011, The Journal of Biological Chemistry.

[64]  P. Meikle,et al.  Postprandial metabolism of docosapentaenoic acid (DPA, 22:5n-3) and eicosapentaenoic acid (EPA, 20:5n-3) in humans. , 2013, Prostaglandins, leukotrienes, and essential fatty acids.

[65]  L. Grégoire,et al.  Docosahexaenoic acid reduces levodopa‐induced dyskinesias in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine monkeys , 2006, Annals of neurology.

[66]  S. Wassall,et al.  Docosahexaenoic acid: membrane properties of a unique fatty acid. , 2003, Chemistry and physics of lipids.

[67]  G Durand,et al.  The effects of dietary alpha-linolenic acid on the composition of nerve membranes, enzymatic activity, amplitude of electrophysiological parameters, resistance to poisons and performance of learning tasks in rats. , 1989, The Journal of nutrition.

[68]  J. Molero,et al.  Orally administered [¹⁴C]DPA and [¹⁴C]DHA are metabolised differently to [¹⁴C]EPA in rats. , 2013, The British journal of nutrition.

[69]  E. Corey,et al.  Docosahexaenoic acid is a strong inhibitor of prostaglandin but not leukotriene biosynthesis. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[70]  E. Park,et al.  Oral Docosapentaenoic Acid (22:5n-3) Is Differentially Incorporated into Phospholipid Pools and Differentially Metabolized to Eicosapentaenoic Acid in Tissues from Young Rats , 2011, Lipids.

[71]  A. A. Spector,et al.  Docosahexaenoic acid synthesis in human skin fibroblasts involves peroxisomal retroconversion of tetracosahexaenoic acid. , 1995, Journal of lipid research.

[72]  P. Tso,et al.  Omega-3 fatty acid deficient male rats exhibit abnormal behavioral activation in the forced swim test following chronic fluoxetine treatment: association with altered 5-HT1A and alpha2A adrenergic receptor expression. , 2014, Journal of psychiatric research.

[73]  C. Serhan,et al.  Resolvins , 2002, The Journal of experimental medicine.

[74]  Zhiming Wen,et al.  Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[75]  Y. Yaari,et al.  α‐Synuclein Neuropathology is Controlled by Nuclear Hormone Receptors and Enhanced by Docosahexaenoic Acid in A Mouse Model for Parkinson's Disease , 2012, Brain pathology.

[76]  A. Gazsó,et al.  [Polyunsaturated fatty acids]. , 1989, Wiener klinische Wochenschrift.

[77]  S. Rapoport,et al.  α‐Linolenic acid does not contribute appreciably to docosahexaenoic acid within brain phospholipids of adult rats fed a diet enriched in docosahexaenoic acid , 2005, Journal of neurochemistry.

[78]  Steven R. Brenner,et al.  Penetrance of PD in Glucocerebrosidase Gene Mutation Carriers , 2012, Neurology.

[79]  T. Teyler.  Long-term potentiation and memory. , 1987, International journal of neurology.

[80]  F. Russell,et al.  Distinguishing Health Benefits of Eicosapentaenoic and Docosahexaenoic Acids , 2012, Marine drugs.

[81]  G. Halliday,et al.  Alpha-synuclein biology in Lewy body diseases , 2014, Alzheimer's Research & Therapy.

[82]  M. Garg,et al.  Short-term docosapentaenoic acid (22 : 5n-3) supplementation increases tissue docosapentaenoic acid, DHA and EPA concentrations in rats , 2009, British Journal of Nutrition.

[83]  N. Bazan,et al.  The docosanoid neuroprotectin D1 induces homeostatic regulation of neuroinflammation and cell survival. , 2013, Prostaglandins, leukotrienes, and essential fatty acids.

[84]  N. Bazan,et al.  Endogenous Signaling by Omega-3 Docosahexaenoic Acid-derived Mediators Sustains Homeostatic Synaptic and Circuitry Integrity , 2011, Molecular Neurobiology.

[85]  C. Song,et al.  Ethyl-eicosapentaenoate (E-EPA) attenuates motor impairments and inflammation in the MPTP-probenecid mouse model of Parkinson's disease , 2012, Behavioural Brain Research.

[86]  M. Lagarde,et al.  Confusion between protectin D1 (PD1) and its isomer protectin DX (PDX). An overview on the dihydroxy-docosatrienes described to date. , 2014, Biochimie.

[87]  F. Calderon,et al.  Docosahexaenoic acid promotes neurite growth in hippocampal neurons , 2004 .

[88]  N. Salem,et al.  An extraordinary degree of structural specificity is required in neural phospholipids for optimal brain function: n‐6 docosapentaenoic acid substitution for docosahexaenoic acid leads to a loss in spatial task performance , 2005, Journal of neurochemistry.

[89]  D. O'Neal,et al.  Lipids in Health and Disease , 2009 .

[90]  M. Lynch,et al.  Apoptotic Changes in the Aged Brain Are Triggered by Interleukin-1β-induced Activation of p38 and Reversed by Treatment with Eicosapentaenoic Acid* , 2002, The Journal of Biological Chemistry.

[91]  R. Paoletti,et al.  Effects of dietary fatty acids on the fatty acid composition of brain ethanolamine phosphoglyceride : Reciprocal replacement of n-6 and n-3 polyunsaturated fatty acids , 1971 .

[92]  P. Worley,et al.  COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[93]  Shiro Watanabe,et al.  Membrane Fatty Acid Modifications of PC12 Cells by Arachidonate or Docosahexaenoate Affect Neurite Outgrowth But Not Norepinephrine Release , 1997, Neurochemical Research.

[94]  J. Whelan.  Dietary stearidonic acid is a long chain (n-3) polyunsaturated fatty acid with potential health benefits. , 2009, The Journal of nutrition.

[95]  Hee-Yong Kim,et al.  Substrate preference in phosphatidylserine biosynthesis for docosahexaenoic acid containing species. , 2004, Biochemistry.

[96]  Ashley C. Patterson,et al.  Assessment of blood measures of n-3 polyunsaturated fatty acids with acute fish oil supplementation and washout in men and women. , 2009, Prostaglandins, leukotrienes, and essential fatty acids.

[97]  S. Serini,et al.  EPA and DHA differentially affect in vitro inflammatory cytokine release by peripheral blood mononuclear cells from Alzheimer's patients. , 2012, Current Alzheimer research.

[98]  M. P. Cole,et al.  Cyclooxygenase-2 generates anti-inflammatory mediators from omega-3 fatty acids. , 2010, Nature chemical biology.

[99]  N. Vassallo,et al.  The Centrality of Mitochondria in the Pathogenesis and Treatment of Parkinson's Disease , 2014, CNS neuroscience & therapeutics.

[100]  Michael Weiner,et al.  Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. , 2010, JAMA.

[101]  S. Rapoport,et al.  Chronic nutritional deprivation of n‐3 α‐linolenic acid does not affect n‐6 arachidonic acid recycling within brain phospholipids of awake rats , 2001, Journal of neurochemistry.

[102]  L. Arterburn,et al.  Distribution, interconversion, and dose response of n-3 fatty acids in humans. , 2006, The American journal of clinical nutrition.

[103]  A. Xie,et al.  Shared Mechanisms of Neurodegeneration in Alzheimer's Disease and Parkinson's Disease , 2014, BioMed research international.

[104]  S. Rapoport,et al.  Brain elongation of linoleic acid is a negligible source of the arachidonate in brain phospholipids of adult rats. , 2006, Biochimica et biophysica acta.

[105]  M. Vohl,et al.  Disturbance in uniformly 13C-labelled DHA metabolism in elderly human subjects carrying the apoE ε4 allele , 2013, British Journal of Nutrition.

[106]  J. Mann,et al.  Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. , 2011, The Journal of clinical psychiatry.

[107]  Rhoda Au,et al.  Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. , 2006, Archives of neurology.

[108]  M. Rashid,et al.  N‐docosahexaenoylethanolamine is a potent neurogenic factor for neural stem cell differentiation , 2013, Journal of neurochemistry.

[109]  Cai Song,et al.  Ethyl-eicosapentaenoate modulates changes in neurochemistry and brain lipids induced by parkinsonian neurotoxin 1-methyl-4-phenylpyridinium in mouse brain slices. , 2010, European journal of pharmacology.

[110]  F. Calon,et al.  Rapid beta-oxidation of eicosapentaenoic acid in mouse brain: an in situ study. , 2009, Prostaglandins, leukotrienes, and essential fatty acids.

[111]  J. Cummings,et al.  Alzheimer’s disease drug-development pipeline: few candidates, frequent failures , 2014, Alzheimer's Research & Therapy.

[112]  I. Denis,et al.  Omega-3 polyunsaturated fatty acids and brain aging , 2015, Current opinion in clinical nutrition and metabolic care.

[113]  A. Michael-Titus,et al.  Neurological Benefits of Omega-3 Fatty Acids , 2008, NeuroMolecular Medicine.

[114]  S. Dyall.  Amyloid-Beta Peptide, Oxidative Stress and Inflammation in Alzheimer's Disease: Potential Neuroprotective Effects of Omega-3 Polyunsaturated Fatty Acids , 2010, International Journal of Alzheimer's Disease.

[115]  L. Svennerholm,et al.  Changes in weight and compositions of major membrane components of human brain during the span of adult human life of Swedes , 1997, Acta Neuropathologica.

[116]  Shih-Yi Huang,et al.  A meta-analytic review of polyunsaturated fatty acid compositions in dementia. , 2012, The Journal of clinical psychiatry.

[117]  A. Blackwell,et al.  Beneficial effects of docosahexaenoic acid on cognition in age-related cognitive decline , 2010, Alzheimer's & Dementia.

[118]  M. Crawford,et al.  The long chain metabolites of linoleic avid linolenic acids in liver and brain in herbivores and carnivores. , 1976, Comparative biochemistry and physiology. B, Comparative biochemistry.

[119]  B. Ames.  Delaying the Mitochondrial Decay of Aging , 2004, Annals of the New York Academy of Sciences.

[120]  R. Holman,et al.  Polyunsaturated fatty acids , 1977 .

[121]  A. Rajput,et al.  Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys , 2006, Neurochemistry International.

[122]  C. Serhan,et al.  Total Synthesis of the Lipid Mediator PD1n-3 DPA: Configurational Assignments and Anti-inflammatory and Pro-resolving Actions , 2014, Journal of natural products.

[123]  J. Halver,et al.  Docosahexaenoic acid-containing phospholipid molecular species in brains of vertebrates. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[124]  R. Ryan,et al.  Impact of apolipoprotein E on Alzheimer's disease. , 2013, Current Alzheimer research.

[125]  K. Linderborg,et al.  Comparison of the bioavailability of docosapentaenoic acid (DPA, 22:5n-3) and eicosapentaenoic acid (EPA, 20:5n-3) in the rat. , 2014, Prostaglandins, leukotrienes, and essential fatty acids.

[126]  Charles N. Serhan,et al.  Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators , 2008, Nature Reviews Immunology.

[127]  F. Calderon,et al.  Docosahexaenoic acid promotes neurite growth in hippocampal neurons , 2004, Journal of neurochemistry.

[128]  S. Dyall.  Methodological issues and inconsistencies in the field of omega-3 fatty acids research. , 2011, Prostaglandins, leukotrienes, and essential fatty acids.

[129]  S. Cunnane,et al.  alpha-Linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans. , 2009, Prostaglandins, leukotrienes, and essential fatty acids.

[130]  D. Abrous,et al.  Spatial memory performances of aged rats in the water maze predict levels of hippocampal neurogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[131]  M. Fornage,et al.  Genetic Loci Associated with Plasma Phospholipid n-3 Fatty Acids: A Meta-Analysis of Genome-Wide Association Studies from the CHARGE Consortium , 2011, PLoS genetics.

[132]  R. Gibson,et al.  Correlations between blood and tissue omega-3 LCPUFA status following dietary ALA intervention in rats. , 2013, Prostaglandins, leukotrienes, and essential fatty acids.

[133]  S. Shaikh,et al.  Docosahexaenoic and eicosapentaenoic acids segregate differently between raft and nonraft domains. , 2012, Biophysical journal.

[134]  R. Wurtman,et al.  Chronic administration of docosahexaenoic acid or eicosapentaenoic acid, but not arachidonic acid, alone or in combination with uridine, increases brain phosphatide and synaptic protein levels in gerbils , 2007, Neuroscience.

[135]  C. Serhan,et al.  Novel n-3 Immunoresolvents: Structures and Actions , 2013, Scientific Reports.

[136]  D. Geschwind,et al.  Dentate Granule Cell Neurogenesis Is Increased by Seizures and Contributes to Aberrant Network Reorganization in the Adult Rat Hippocampus , 1997, The Journal of Neuroscience.

[137]  G. Santpere,et al.  Severe Alterations in Lipid Composition of Frontal Cortex Lipid Rafts from Parkinson’s Disease and Incidental Parkinson’s Disease , 2011, Molecular medicine.

[138]  M. Faulkner.  Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson’s disease , 2014, Expert opinion on drug safety.

[139]  D. Dewitt,et al.  Characterization of inducible cyclooxygenase in rat brain , 1995, The Journal of comparative neurology.

[140]  M. Romero-Ramos,et al.  The relation between α-synuclein and microglia in Parkinson’s disease: Recent developments , 2015, Neuroscience.

[141]  A. Dale,et al.  What is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus , 2014, Progress in Neurobiology.

[142]  W. A. van der Donk,et al.  Comparison of the properties of prostaglandin H synthase-1 and -2. , 2003, Progress in lipid research.

[143]  W. Gordon,et al.  Docosahexaenoic acid signalolipidomics in nutrition: significance in aging, neuroinflammation, macular degeneration, Alzheimer's, and other neurodegenerative diseases. , 2011, Annual review of nutrition.

[144]  J. Trygg,et al.  Individual Variation in Lipidomic Profiles of Healthy Subjects in Response to Omega-3 Fatty Acids , 2013, PloS one.

[145]  Cécile Proust-Lima,et al.  Plasma long-chain omega-3 fatty acids and atrophy of the medial temporal lobe , 2012, Neurology.

[146]  张静,et al.  Banana Ovate family protein MaOFP1 and MADS-box protein MuMADS1 antagonistically regulated banana fruit ripening , 2015 .

[147]  D. Roberts,et al.  Erythrocyte eicosapentaenoic acid versus docosahexaenoic acid as a marker for fish and fish oil consumption. , 1991, Prostaglandins, leukotrienes, and essential fatty acids.

[148]  L. Bubacco,et al.  α-Synuclein Oligomers Induced by Docosahexaenoic Acid Affect Membrane Integrity , 2013, PloS one.

[149]  M. Vila,et al.  The Parkinson Disease Mitochondrial Hypothesis , 2016, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[150]  R. Emsley,et al.  The effects of eicosapentaenoic acid in tardive dyskinesia: A randomized, placebo-controlled trial , 2006, Schizophrenia Research.

[151]  P. Barberger‐Gateau,et al.  Plasma eicosapentaenoic acid is inversely associated with severity of depressive symptomatology in the elderly: data from the Bordeaux sample of the Three-City Study. , 2008, The American journal of clinical nutrition.

[152]  Cai Song,et al.  Omega‐3 fatty acid eicospentaenoic acid attenuates MPP+‐induced neurodegeneration in fully differentiated human SH‐SY5Y and primary mesencephalic cells , 2013, Journal of neurochemistry.

[153]  J. Viña,et al.  Molecular mechanisms linking amyloid β toxicity and Tau hyperphosphorylation in Alzheimer׳s disease. , 2015, Free radical biology & medicine.

[154]  L. Robson,et al.  Omega-3 polyunsaturated fatty acids increase the neurite outgrowth of rat sensory neurones throughout development and in aged animals , 2010, Neurobiology of Aging.

[155]  R. Garavito,et al.  Cyclooxygenases: structural, cellular, and molecular biology. , 2000, Annual review of biochemistry.

[156]  S. Wassall,et al.  Docosahexaenoic acid domains: the ultimate non-raft membrane domain. , 2008, Chemistry and physics of lipids.

[157]  Sunia A Trauger,et al.  Metabolic oxidation regulates embryonic stem cell differentiation , 2010, Nature chemical biology.

[158]  M. Bloch,et al.  Omega-3 Fatty Acids for the Treatment of Depression: Systematic Review and Meta-Analysis , 2011, Molecular Psychiatry.

[159]  T. Palmer,et al.  Neurogenesis in the dentate gyrus of the adult rat: age-related decrease of neuronal progenitor proliferation , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[160]  D. Cameron-Smith,et al.  A short-term n-3 DPA supplementation study in humans , 2013, European Journal of Nutrition.

[161]  Carol A. Barnes,et al.  Expression of a mitogen-inducible cyclooxygenase in brain neurons: Regulation by synaptic activity and glucocorticoids , 1993, Neuron.

[162]  A. Nagar,et al.  A quantum theory for the irreplaceable role of docosahexaenoic acid in neural cell signalling throughout evolution. , 2013, Prostaglandins, leukotrienes, and essential fatty acids.